Cognition Therapeutics Data Shows Retinal Cell Health Impact
Clinical Trial Vanguard
By Jon Napitupulu
May 12, 2025
Cognition Therapeutics Data Shows Retinal Cell Health Impact Read More »
Zervimesine Robustly Slows Geographic Atrophy Lesion Growth in Latest Phase 2 MAGNIFY Data
Neurology Live
By Marco Meglio
May 10, 2025
Oral zervimesine reduced GA lesion growth in phase 2 study from Cognition Therapeutics
Ophthalmology Times
By Emily Kaiser Maharjan
May 8, 2025
Oral zervimesine reduced GA lesion growth in phase 2 study from Cognition Therapeutics Read More »
Hamby ME, Kavanagh S, Di Caro V, et al. Positive Impact of CT1812 Treatment on Plasma Biomarkers in Lower p-tau217 Subgroup Aligns with Clinical Benefits in Mild-to-Moderate AD Patients. Poster presented at AD/PD 2025; Vienna, Austria
Di Caro V, Cho E, Lizama B, et al. Identification of Molecular Correlates with CT1812 Treatment-related decrease in NfL CSF Levels Connected to Sigma-2 Receptor. Poster presented at AD/PD 2025; Vienna, Austria
Lizama BN, Pandey K, Duong D, et al. CSF Proteomic Biomarker Analysis from Phase 2 Study SHINE Identified Effects of S2R Modulator CT1812 in Alzheimer’s Disease. Poster presented at AD/PD 2025; Vienna, Austria
Lizama BN, Pandey K, Duong D, et al. Identification of CSF Proteins that Correlate with Cognitive Outcomes in Participants of Phase 2 Study SHINE evaluating Effects of CT1812 in Patients with Alzheimer’s Disease. Poster presented at AD/PD 2025; Vienna, Austria
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
